Share this article
Share this article
Challenged by Similar Clinical Presentations, Accurate Detection & Differentiation of all 4 Viruses is Critical for Clinicians This Flu Season
SUNNYVALE, Calif., Jan. 14, 2021 /CNW/ Cepheid today announced that Health Canada has issued Cepheid a medical device license for Xpert
® Xpress
SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The test is now available in Canada and can be used in laboratories and at the point of care. The four-in-one test is designed for use on any of Cepheid s almost 30,000 GeneXpert